Antidepressant use does not worsen early outcomes after traumatic brain injury

A new study published January 28, 2026, in Neurology^® indicates that taking certain antidepressants does not negatively impact short-term outcomes for individuals hospitalized with traumatic brain injury (TBI). Researchers found no association between antidepressant use and increased risk of death, the need for brain surgery, or length of hospital stay.

Understanding the Study

The research focused on serotonergic antidepressants – medications commonly prescribed for anxiety and depression that work by influencing serotonin levels in the brain. These include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). The study analyzed data from 54,876 people in Finland, age 16 and older, who were hospitalized due to TBI.

Did You Know? Researchers reviewed national prescription records and medical records to assess antidepressant use, mortality rates, surgical interventions, and hospital stay durations.

Researchers examined national prescription records to determine prior antidepressant use and reviewed medical records to track outcomes. Of those hospitalized for TBI, 14% were taking serotonergic antidepressants at the time of their injury. A total of 4,105 people died within a month of their injury, representing 7.6% of those taking antidepressants and 7.5% of those who were not.

Surgery and Hospital Stay

After accounting for factors like age, sex, and other health conditions, the study revealed that individuals taking antidepressants were not more likely to die within a month compared to those not taking them. Interestingly, antidepressant users were slightly less likely to require emergency brain surgery. Specifically, 6.8% of antidepressant users needed emergency brain surgery, compared to 8.6% of those not using antidepressants – an 11% lower risk after adjustments.

Expert Insight: The findings offer a degree of reassurance to both patients and physicians, suggesting that continuing or initiating antidepressant therapy doesn’t appear to exacerbate early recovery challenges following a traumatic brain injury.

The length of hospital stays was consistent between both groups.

What Could Happen Next

The study’s author, Jussi P. Posti, MD, PhD, of the University of Turku in Finland, indicated that future research should investigate whether these findings extend to long-term recovery and apply to diverse healthcare systems. It is possible that further studies could explore the impact of specific antidepressant types or dosages on TBI outcomes. Researchers may also seek to understand if these results are consistent across different populations and injury severities.

It’s also possible that investigations could expand to include other medications commonly used to treat mental health conditions, to determine if similar patterns emerge. Analyses could also focus on identifying potential subgroups of TBI patients who might benefit most – or least – from continued antidepressant use.

Frequently Asked Questions

What types of antidepressants were included in the study?

The study looked at serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs).

How many people participated in the study?

The study included 54,876 people in Finland who were 16 or older when hospitalized with a TBI.

Did the study find any negative effects of antidepressants after a TBI?

The study found no evidence that taking these antidepressants increased the risk of death, brain surgery, or longer hospital stays after a traumatic brain injury.

Given these findings, how might this information influence conversations between doctors and patients regarding mental health treatment following a brain injury?